Treatment of murine cryptococcal meningitis with an SCH 39304-amphotericin B combination

Cryptococcal meningitis was induced in BALB/c mice by intracerebral infection with Cryptococcus neoformans. Drug therapy was initiated 1 day later, with mice receiving amphotericin B (AMB), SCH 39304, combination therapy, or no drug therapy (controls). Most, but not all, combinations showed additive benefits, significantly prolonging survival and reducing organism counts in tissues compared with those in controls and groups which received the drugs independently. Optimum protection was obtained when a single dose of 10 mg of AMB per kg of body weight was combined with a fairly narrow SCH 39304 dose range. AMB antagonism did not occur with any regimen tested. AMB-azole combinations may be reasonable alternatives for patients who fail standard cryptococcosis therapeutic regimens.

[1]  N. Mocsny.  Cryptococcal Meningitis in Patients with AIDS , 1992, The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses.

[2]  B. Dupont,et al.  Overview: treatment of cryptococcal meningitis. , 1990, Reviews of infectious diseases.

[3]  J. Graybill,et al.  Efficacy of SCH39304 in murine cryptococcosis , 1989, Antimicrobial Agents and Chemotherapy.

[4]  A. Pablos-Mendez,et al.  Infections associated with Hickman catheters in patients with acquired immunodeficiency syndrome. , 1989, The American journal of medicine.

[5]  M. Rinaldi,et al.  Assay of fluconazole by megabore capillary gas-liquid chromatography with nitrogen-selective detection , 1989, Antimicrobial Agents and Chemotherapy.

[6]  D. Armstrong,et al.  Life‐Threatening Opportunistic Fungal Infection in Patients with the Acquired Immunodeficiency Syndrome , 1988, Annals of the New York Academy of Sciences.

[7]  J. Sculier,et al.  Amphotericin B Encapsulated in Liposomes Administered to Cancer Patients a , 1988, Annals of the New York Academy of Sciences.

[8]  G. Lopez-Berestein.  Liposomes as Carriers of Antifungal Drugs , 1988, Annals of the New York Academy of Sciences.

[9]  B. Wentworth.  Diagnostic Procedures for Mycotic and Parasitic Infections , 1988 .

[10]  W. Dismukes.  Cryptococcal meningitis in patients with AIDS. , 1988, The Journal of infectious diseases.

[11]  M. Saag,et al.  Azole antifungal agents: emphasis on new triazoles , 1988, Antimicrobial Agents and Chemotherapy.

[12]  R. Diasio,et al.  Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. , 1987, The American journal of medicine.

[13]  G. Medoff.  Controversial areas in antifungal chemotherapy: short-course and combination therapy with amphotericin B. , 1987, Reviews of infectious diseases.

[14]  G. Medoff,et al.  Amphotericin B-induced oxidative damage and killing of Candida albicans. , 1986, The Journal of infectious diseases.

[15]  G. Medoff,et al.  Sensitivity of Candida albicans to amphotericin B administered as single or fractionated doses , 1986, Antimicrobial Agents and Chemotherapy.

[16]  E. Gelmann,et al.  Cryptococcosis in the acquired immunodeficiency syndrome. , 1985, Annals of internal medicine.

[17]  A. Schaffner,et al.  The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis. , 1985, The Journal of infectious diseases.

[18]  J. Reuben,et al.  Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. , 1985, The Journal of infectious diseases.

[19]  H. Vanden Bossche.  Biochemical targets for antifungal azole derivatives: hypothesis on the mode of action. , 1985, Current topics in medical mycology.

[20]  H. van den Bossche,et al.  Hypothesis on the molecular basis of the antifungal activity of N-substituted imidazoles and triazoles. , 1983, Biochemical Society transactions.

[21]  J. Bolard,et al.  Differences in the interaction of the polyene antibiotic amphotericin B with cholesterol- or ergosterol-containing phospholipid vesicles. A circular dichroism and permeability study. , 1983, Biochemistry.

[22]  J. Washington,et al.  Discrepancies between in vitro activity of and in vivo response to antimicrobial agents. , 1983, Diagnostic microbiology and infectious disease.

[23]  A. Polak,et al.  Combination therapy of experimental candidiasis, cryptococcosis and aspergillosis in mice. , 1982, Chemotherapy.

[24]  E. Van Cutsem,et al.  Combination therapy of experimental histoplasmosis and cryptococcosis with amphotericin B and ketoconazole. , 1980, Reviews of infectious diseases.

[25]  G. Medoff,et al.  Strategies in the treatment of systemic fungal infections. , 1980, The New England journal of medicine.

[26]  J. Galgiani,et al.  Turbidimetric Studies of Growth Inhibition of Yeasts with Three Drugs: Inquiry into Inoculum-Dependent Susceptibility Testing, Time of Onset of Drug Effect, and Implications for Current and Newer Methods , 1978, Antimicrobial Agents and Chemotherapy.

[27]  D. Schlessinger,et al.  Sensitivity to amphotericin B and the cholesterol: phospholipid molar ratios of 3T3, L, BHK and HeLa cells. , 1977, Biochemical pharmacology.